Which condition can have a normal Diffusion capacity of carbon monoxide (DLCO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The answer to the question is A. Asthma, as it is the only condition listed that can have a normal diffusion capacity of carbon monoxide (DLCO) due to its primary effect on the airways rather than the alveolar-capillary interface. Among the conditions listed, asthma is distinct because it primarily affects the airways, leading to bronchial hyperresponsiveness, inflammation, and reversible airflow obstruction, without directly impairing the alveolar membrane and pulmonary capillary blood volume. In contrast, pulmonary hypertension, pulmonary fibrosis, and severe COPD involve structural changes that directly impair gas exchange across the alveolar-capillary membrane, resulting in reduced DLCO values. Pulmonary hypertension reduces the vascular bed available for gas exchange 1, pulmonary fibrosis thickens the alveolar-capillary membrane, and severe COPD often involves destruction of alveolar walls and reduced capillary blood volume, particularly in emphysema. Understanding this distinction is crucial for differentiating asthma from other pulmonary conditions when interpreting pulmonary function tests, as noted in guidelines for the diagnosis and treatment of pulmonary hypertension 1. Asthma's characteristic high or high normal DLCO value is highlighted in the evaluation of patients with refractory asthma, where a low diffusing capacity suggests alternative diagnoses such as emphysema, pulmonary vascular disease, or interstitial lung disease 1. Therefore, when considering the conditions listed, asthma stands out as the one that can present with a normal DLCO, making it the correct answer based on the pathophysiology of these diseases and their effects on lung function.

From the Research

Conditions with Normal Diffusion Capacity of CO (DLCO)

The following conditions can have a normal DLCO:

  • Asthma: According to 2, single breath diffusing capacity for carbon monoxide (Dco) is commonly used as a simple method of assessing overall pulmonary gas exchange properties, and studies of Dco in bronchial asthma have yielded conflicting results. However, the mean value of Dco was increased to 117% of predicted values in patients with uncomplicated stable asthma.
  • Pulmonary hypertension: Although 3 suggests that the FVC/DLCO ratio can be used to predict pulmonary hypertension in patients with COPD, it does not necessarily imply that DLCO is abnormal in all cases of pulmonary hypertension.

Conditions with Abnormal DLCO

The following conditions are associated with abnormal DLCO:

  • Pulmonary fibrosis: While not directly mentioned in the provided studies, pulmonary fibrosis is known to affect gas exchange and can lead to reduced DLCO.
  • Severe COPD: According to 4 and 5, DLCO is significantly reduced in patients with COPD, especially in those with severe disease.

Key Findings

  • Asthma patients can have normal or high DLCO values, as shown in 2 and 6.
  • COPD patients tend to have lower DLCO values, especially in severe cases, as demonstrated in 4 and 5.
  • The FVC/DLCO ratio can be used to predict pulmonary hypertension in patients with COPD, as suggested in 3.

Related Questions

What are the causes of a low DLCO on pulmonary function tests (PFTs)?
How should the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) be interpreted?
When is a Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) considered increased?
What is considered a significant increase in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)?
Can Pulmonary Function Tests (PFTs) assess Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)?
What are the optimal management and potential missing components in the treatment of an 82-year-old male with a past medical history (PMHx) of ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI), hypertension (HTN), and hyperlipidemia (HLD), admitted with acute decompensated heart failure (ADHF) and frequent monomorphic premature ventricular contractions (PVCs), currently on Aspirin (acetylsalicylic acid) 81 mg/day, Atorvastatin 80 mg/day, Dapagliflozin 10 mg/day, Metoprolol Tartrate 12.5 mg twice daily, Spironolactone 12.5 mg/day, and Furosemide 80 mg twice daily intravenously?
What are the potential health effects of water contaminants, and are certain individuals, such as those with compromised immune systems, more susceptible to adverse effects?
What is the cause of a 31-year-old female's left radial wrist swelling and discomfort without trauma or fever?
What are the safety concerns regarding the use of tap water for cooking, showering, and oral hygiene?
Is there a difference in effectiveness between oral loperamide (Loperamide) tablets and liquid formulations?
What are the discharge instructions for a mother regarding her child's diagnosis of otitis media (inflammation of the middle ear)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.